Objectives

Objective 1: To investigate the association of *VTCN1* polymorphisms and *VTCN1* and *NRD1* transcript levels with vitiligo susceptibility in Gujarat population.

- a) Genotyping of *VTCN1* rs10923223 and rs12046117 polymorphisms in vitiligo patients & controls.
- b) Estimation of *VTCN1* and *NRD1* transcript levels from PBMCs of vitiligo patients & controls.
- c) Estimation of *VTCN1* and *NRD1* transcript levels from skin of vitiligo patients & controls.

Objective 2: To determine VTCN1 and NRD1 protein expression in vitiligo patients and controls.

- a) Estimation of VTCN1 protein expression in the skin samples of vitiligo patients & controls.
- b) Estimation of plasma soluble VTCN1 (sVTCN1) levels in vitiligo patients and controls.
- c) Estimation of plasma soluble NRD1 levels in vitiligo patients and controls
- d) Correlation of sVTCN1 levels with NRD1 in vitiligo patients.

Objective 3: To carry out immunophenotypic analysis of VTCN1 in vitiligo patients

- a) Estimation of VTCN1 expression on different immune cell subpopulations from blood of vitiligo patients.
- b) Estimation of VTCN1 expression on different immune cell subpopulations from skin of vitiligo patients.

Objective 4: To study the effect of pro-inflammatory & anti-inflammatory cytokines on VTCN1 expression and STAT3 activation.

a) Assessment of the VTCN1 expression and activation of STAT3 upon cytokines' (TNF- α , IFN- γ and IL-10) treatment in THP1 cell line.

Role of negative co-stimulatory molecule V-set domain containing T-cell activation inhibitor-1 (VTCN1) in Vitiligo pathogenesis